New CEO at Celesio subsidiary pharmexx
With immediate effect, Reto Flückiger will head the Celesio subsidiary pharmexx GmbH, a globally operating personnel and marketing service provider for the pharmaceutical industry. Likewise with immediate effect, Georg Nagl has been appointed Chief Operating Officer (COO) and chairman of the pharmexx advisory board.
Flückiger is a 44-year-old business economist from Switzerland with more than 14 years of experience in managerial marketing and sales positions in the pharmaceutical industry. His last role was member of the management board at A.T. Kearney, one of the leading strategic management consultancies worldwide, where he focused on the pharmaceutical and healthcare sector. Previously, he has worked in various positions for Merck Sharp & Dohme-Chibret (MSD). As a member of the management board in Switzerland he was head of the business segment Osteoporosis and Asthma. Moreover, at the MSD headquarters in New Jersey Reto Flückiger was responsible for strategic projects in the US and Europe as well as marketing projects.
pharmexx’s new Chief Operating Officer (COO), Georg Nagl, has been working for the company since 1999, his last position was CEO. Together with Michael Schomaker, the 44-year-old microbiologist established pharmexx as one of the leading Contract Sales Organisations (CSO) worldwide. 54-year-old Michael Schomaker used to be pharmexx’s COO and will now be responsible for the regions Latin America and South East Asia.
On 3 July 2009, Celesio received the approval of the European Commission, according to anti-trust regulations, to acquire a majority stake in pharmexx GmbH.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
